您的当前位置:首页 > 行业数据 > AK112联合化疗在鳞癌和非鳞癌均优于K药联合化疗(非头对头)
图片属性
图片格式:PNG 图片大小:87KB 图片尺寸:1771*733
同报告图片
 / 4
AK112联合化疗在鳞癌和非鳞癌均优于K药联合化疗(非头对头)_第1页
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
AK112联合化疗在鳞癌和非鳞癌均优于K药联合化疗(非头对头)_第2页
AK112联合化疗在鳞癌和非鳞癌均优于K药联合化疗(非头对头)_第3页
AK112联合化疗在鳞癌和非鳞癌均优于K药联合化疗(非头对头)_第4页
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
AK112联合化疗在鳞癌和非鳞癌均优于K药联合化疗(非头对头)_第5页
fCDliIbmnJ8gfCDmlbDph48gfAp8IC0tLSB8IC0tLSB8CnwgSUlJ5pyfIHwgOTIgfAp8IEkvSUnmnJ8gfCA4NiB8CnwgSUnmnJ8gfCAyOTYgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM5Y2O56aP6K+B5Yi456CU56m25omA77yI5oiq6IezMjAyNOW5tDbmnIgyNeaXpe+8iQ==
所属报告: 康方生物-港股公司研究报告-肺癌大适应症先发优势占位IO 2.0的未来已来-240708(31页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠